Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

SELECT - SEMAGLUTIDE EFFECTS ON CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT OR OBESITY

Intervention/treatment:
SEMAGLUTIDE S.C.
Medical condition:
OVERWEIGHT/OBESITY
Protocol code:
EX9536-4388
Control number:
212550
Status:
Closed
Approved:
July 25, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03574597
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
45 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Reporting Office (2834)
Organization
Novo Nordisk A/S
Phone:
(+1) 866-867-7178
Sponsor
NOVO NORDISK CANADA INC

Locations

Alberta

C-endo Diab Endo Clin Calgery
Calgary, Alberta, T2V 4J2
Synergy Wellness Clinic
Sherwood Park, Alberta, T8H 0N2
University of Calgary
Calgary, Alberta, T2T 5C7

New Brunswick

G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7

Ontario

Cambridge Cardiac Care Centre
Cambridge, Ontario, N1R 6V6
Dr. James Cha
Oshawa, Ontario, L1J 2K1
HHI Research Inc.
Scarborough Village, Ontario, M1B 4Z8
Institut universitaire de cardiologie
Québec, Ontario, G1V 4G5
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, K9J 0B2
Manna Research Inc. (Burlington N)
Burlington, Ontario, L7M 4Y1
Manna Research Inc._Toronto
Toronto, Ontario, M9W 4L6
Manna Research Ottawa
Nepean, Ontario, K2J 4A7
Manna Research Stoney Creek
Stoney Creek, Ontario, L8J 3W2
Medical Associates of Port Perry
Port Perry, Ontario, L9L 1L9
North York Diagn & Cardiac Ctr
North York, Ontario, M6B 3H7
St. Joseph's Health Care
London, Ontario, N6A 4V2
The Port Arthur Clinic Research Program
Thunder Bay, Ontario, P7A 4V7

Quebec

Applied Med Inf Res
Montreal, Quebec, H4A 3T2
Centre de recherché du CHUS
Sherbrooke, Quebec, J1H 5N4
Centre de santé et de services
Terrebonne, Quebec, J6V 2H2
Centricity Res Pointe-Claire
Pointe-Claire, Quebec, H9R 4S5
Clin des Mal Lipid de Quebec
Québec, Quebec, G1V 4W2
Clinique Sante Cardio MC
Montreal, Quebec, H1T 3Y7
Ctr Méd. et pro d l'Ost d port
Saint-Marc-des-Carrieres, Quebec, G0A 4B0
IRCM
Montreal, Quebec, H2W 1R7
Manna Research Mirabel
Mirabel, Quebec, J7J 2K8
Manna Research Quebec
Lévis, Quebec, G6W 0M5
ViaCar Recherche Clinique Inc
Brossard, Quebec, J4Z 2K9

Results

See the results from the trial NCT03574597. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?